TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00502281
Drug: highly purified urinary FSH
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01719926
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 times per day from 2 days before until 5 days after chemotherapy. Escalating dosage each cohort.
Study: NCT00479947
Drug: Probiotics (Natural product)
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00479947
Drug: Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14)
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00044538
Drug: BAY59-8862 (Cytotoxic Taxane)
Normalized name: Taxanes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dose over 60 minutes every 3 weeks
Study: NCT05455944
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two identical placebo capsules is administered orally to patients
Study: NCT02634255
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02266485
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00123552
Drug: Artemether+Lumefantrine
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether 20 mg + Lumefantrine 120 mg 6 dose regimen at 0 and 8 hours on day 1 and twice daily on days 2 and 3:5 kg to \< 15 kg: 1 tab/dose; 15 to 24 kg: 2 tabs/dose; \>35 kg:4 tabs per dose
Study: NCT03446001
Drug: TRx0237 16 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TRx0237 4-mg tablets administered twice daily
Study: NCT02266485
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03446001
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo tablets (some of which contain a urinary discolorant) administered twice daily
Study: NCT04166890
Drug: Articaine / EPINEPHrine Cartridge
Normalized name: articaine / epinephrine Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: The day scheduled for the surgery, vital signs (pulse, blood pressure and oxygen saturation) will be recorded prior the administration of the anesthesia. A volume of 1.8 ml of 4% articaine and epinephrine 1: 100000 solution of either the test product or the reference product will be deposited slowly to proceed to the inferior alveolar nerve block (IANB), according to the table of allocation of treatments in each period. The vital signs will continue to be monitored during the procedure, and once the procedure has been completed. If the volunteer needs more anesthetic, this will be recorded and will be administrated according to the maximum permitted doses (7 mg / kg (up to 500 mg) 5 mg / kg in children 7), and immediately after the administration, the vital signs will be taken again.
Study: NCT00930618
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 2 X 20 mg of placebo of IMN at each administration with a maximum of three administration
Study: NCT02125240
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet three times daily by mouth
Study: NCT03446001
Drug: TRx0237 8 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TRx0237 4-mg tablet administered twice daily
Study: NCT00003650
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003650
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003650
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01097785
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg, P.O.,daily for 30 days
Study: NCT01097785
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule daily for 30 days
Study: NCT00118833
Drug: Hypericum perforatum (St. John's wort)
Normalized name: HYPERICUM PERFORATUM (ST. JOHN'S WORT)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03940053
Drug: Arginine hydrochloride
Normalized name: Arginine Hydrochloride
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days. Treatment is continued until the levels of tumor marker dropped to normal
Study: NCT03165929
Drug: Flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral flurbiprofen spray
Study: NCT03165929
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo spray
Study: NCT01449565
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 monthly intramuscular injections of placebo, matched to naltrexone 380 mg (extended release)
Study: NCT00709189
Drug: Norgestimate/Ehinyl Estradiol; Folic acid.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02592824
Drug: saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of saline at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
Study: NCT00701233
Drug: Corticosteroid injection into Carpal Tunnel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Triamcinolone with one mL 1% lidocaine injected once into Carpal Tunnel
Study: NCT05535036
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients received 2ml of intravenous saline solution
Study: NCT04128917
Drug: RAPAE01
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAPAE01/Clarithromycin/Amoxicillin BID peroral
Study: NCT02118285
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 30 mg/kg IV on days -5 and -4 from NK cell infusion
Study: NCT02118285
Drug: INCB024360
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB024360 at assigned dose by mouth twice a day begin day -2 and continue for 90 days (+/- 3 days)
Study: NCT02240680
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo matching linagliptin 5 mg
Study: NCT04311073
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV normal saline 50 ml will be given 15 minutes prior to initial surgical incision in the placebo group.
Study: NCT02034435
Drug: Epleronone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg daily
Study: NCT04502966
Drug: Dupixent® Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose followed by a single injection administered every other week.~Dupixent® placebo is a subcutaneous injection whose composition is identical to the active Dupixent®, with the exception of the active pharmaceutical ingredient.
Study: NCT04502966
Drug: Grazax® Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of Placebo (for Grazax®) daily, by sublingual administration.~Grazax® placebo is a tablet whose composition is identical to the active Grazax® tablet with the only exception being exclusion of the active pharmaceutical ingredient, Phleum pratense Standardized Quality Tablet (SQ-T) units.
Study: NCT00553423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 30 ml q6hrly for 48 hrs
Study: NCT01382550
Drug: long-lasting OAT or 12-month OAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: The antithrombotic treatment will be decided according to usual practice of enrolling Centers. The duration of the initial treatment with parenteral anticoagulation (Low Molecular Weight Heparin or Fondaparinux), the beginning of oral anticoagulation (OAT) with Vit K inhibitors and the International Normalized Ratio (PT-INR) target will be recorded.~According to Center indications the OAT duration (6 months, 12 months or long-lasting) will be recorded and population will be stratified accordingly. The length of therapy will be counted from the date when a stable PT-INR is achieved.~The occurrence of surgery, trauma, prolonged immobilization (\>7 days), pregnancy (VTE risk periods) during the follow-up and the use of adequate anti-thrombotic prophylaxis will be recorded.
Study: NCT03498261
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00988195
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weeks 13-24 (once every 3 weeks)
Study: NCT03019185
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule containing an inert placebo
Study: NCT00250679
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nebule or placebo aerolizer
Study: NCT00624923
Drug: Salsalate
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salsalate, 500 mg, seven tablets daily by mouth, divided into two doses, for 30 months
Study: NCT00624923
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to Salsalate, seven tablets daily by mouth, divided into two doses, for 30 months
Study: NCT02653937
Drug: Tsumura's shigyakusan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shigyakusan appears in the early 3rd Century. Four herbal crude medicines included are the following:~Root of Bupleurum falcatum L Unripe fruit of Citrus aurantium Linne var. daidai Makino, Citrus aurantium Linne, or Citrus natsu-daidai Hayata (Rutaceae) Root of Paeonia lactiflora Pall Root and stolon of Glycyrrhiza uralensis Fisher or Glycyrrhiza glabra Linne
Study: NCT02556060
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same dosing schedule as study drug
Study: NCT02698969
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanest will be administered 2 mcg\*kg-1 at the induction of general anesthesia and titrated 0.5 mcg\*kg-1 every 30 minutes
Study: NCT03835117
Drug: Wide-spectrum nutritional supplement
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive powder with 33 dietary supplements and 1 dietary supplement via gel capsule.
Study: NCT01749904
Drug: BOL-303259-X
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning for 3 months (visit 6).
Study: NCT01166087
Drug: Fluoxetine Hydrochloride
Normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine Hydrocloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories.
Study: NCT03230487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 - single rising dose. Part 2 multiple rising dose
Study: NCT04685226
Drug: ICP-723
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICP-723 is a white, round, uncoated table
Study: NCT02303574
Drug: AZD7986, oral solution, 1 to 50 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose in single ascending dose part: 5 mg
Study: NCT01697787
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: If necessary, the study drug will be crushed, dissolved in water and squirted into the mouth using a spoonful. Administration of the treatments will be directly observed. After drug administration, patients will be kept for at least 30 minutes in the clinic. A dose will be repeated in full if vomiting occurs within 30 minutes of administration and halved if vomiting is between 30 minutes and 1 hour post dosing.
Study: NCT02244632
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV injection every second week for 8 weeks.
Study: NCT01873677
Drug: M518101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01873677
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01606189
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contains peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum daily exposure was set at 48 actuations per day.
Study: NCT00908856
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single intravenous transfusion of saline, approximately 2-21 days after bone marrow aspiration, and 4-23 days after stroke onset; the full amount of mononuclear cells derived from 30 cc of bone marrow
Study: NCT01218802
Drug: Rosuvastatin 10 mg. daily for 96 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take Rosuvastatin 10 mg. daily for 96 weeks.
Study: NCT01218802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants will take a sugar pill daily for 96 weeks
Study: NCT00515164
Drug: Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel
Normalized name: REDUCTIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL Hydrogel
Study: NCT01041859
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form= tablet, route= oral use. Matching placebo twice daily.
Study: NCT01952652
Drug: Group N:Naproxen sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug will be given 60 minutes before surgery
Study: NCT01952652
Drug: Group NC :naproxen sodium codeine phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug will be given 60 minutes before surgery
Study: NCT01354938
Drug: Clarithromycin modified release 500 mg
Normalized name: clarithromycin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin modified release 500 mg was prescribed. The dosage given was either 1 tablet or 2 tablets once a day, depending on the severity of the treatment.
Study: NCT01167023
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally, once daily for 30 days.
Study: NCT03451162
Drug: DHES0815A
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHES0815A will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle.
Study: NCT00609765
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Every 28 Days: Fluorouracil 400mg/m\^2 iv bolus daily days 1-5
Study: NCT00609765
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Every 28 Days: Doxorubicin 40mg/m\^2 iv bolus day 1
Study: NCT00410384
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
Study: NCT00634062
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 12.5mg of inert placebo per day during the first week of the study. Inert placebo can be increased to 25mg per day during the second week of the study and by 25mg per day each week for the next 9 weeks. Subjects can receive a total of 12 weeks of placebo.
Study: NCT02462265
Drug: Oshadi D & Oshadi R;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oshadi D (180mg/TID) \& Oshadi R (180mg TID) will be administrated;
Study: NCT00429702
Drug: Decadron®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00429702
Drug: Benadryl®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00309517
Drug: Fluourouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00309517
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00312143
Drug: Enteric-coated Mycophenolate sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01880827
Drug: MMS
Normalized name: Cystemms-V
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood flow and volume after meal solution
Study: NCT00086671
Drug: ABT-874/Human monoclonal antibody against IL-12
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00086671
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00843362
Drug: Dinoprostone vaginal pessary
Normalized name: dinoprostone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg controlled-release dinoprostone pessary applied for 24 hours
Study: NCT00843362
Drug: Dinoprostone vaginal gel
Normalized name: dinoprostone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg vaginal dinoprostone gel, two daily doses with a 6 hours interval
Study: NCT04700319
Drug: CD19/CD20 CAR-T cell infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19/CD20 CAR-T,Infusion,iv,0.2×10\^6-5×10\^6γδT /kg,once
Study: NCT00602901
Drug: Usual medical care
Normalized name: benzethonium Medicated Liquid Soap [Bedside-Care]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celebrex: po, 200mg, qd, six weeks; Aleve: po, 220mg, bid, six weeks; Bextra: po, 10mg, qd, six weeks; Naproxen: po, 500mg, bid, six weeks.
Study: NCT00201747
Drug: CPT-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT-11 will be administered intravenously on days 2 and 9 (24 hours after MMC, when the MMC is required) Two weeks of rest (beginning days 15 and 22) (drug free) will complete the cycle, with therapy planned to be resumed on day 29.
Study: NCT00630539
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet per day, orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
Study: NCT02293915
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: simulant of sodium oligo-mannurarate capsule
Study: NCT02637960
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One daily dose of placebo (matched to fedovapagon) for 12 weeks
Study: NCT00448123
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02107053
Drug: IV iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV iron is routinely administered to dialysis patients worldwide to correct anemia
Study: NCT04405336
Drug: women who will not receive tab block or PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: no tab block or PCA will be given
Study: NCT02483884
Drug: [68Ga]RM2
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[68Ga\]RM2 is a novel 68Ga labeled, radiopharmaceutical agent for PET imaging. It is administered intravenously as a single dose of 140 MBq (corresponding to ≤ 40 μg mass dose)
Study: NCT00848497
Drug: Testim®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testim® 5 g of gel (one tube) containing 50 mg of testosterone once daily. This was the dose given to the patient which he started.
Study: NCT00848497
Drug: Viagra®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viagra 25mg was the dose given to the patient which he started.
Study: NCT02644018
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00910234
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline is administered 0.5/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
Study: NCT00349336
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As prescribed
Study: NCT00349336
Drug: FOLFOX-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT00696904
Drug: ABT-333
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, see arms for intervention description
Study: NCT00696904
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, see arms for intervention description
Study: NCT02350361
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03513588
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, 0 mg, 14 days, every 12 hours
Study: NCT00003336
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
Study: NCT01768520
Drug: Enteron tab. 150mg(vitis vinifera extract 150mg) : twice daily for 12 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. morning : 1 tab. of active Entelon 150mg plus 1 cap. of placebo Celebrex~2. evening : 1 tab. of active Entelon 150mg
Study: NCT01768520
Drug: Celebrex cap. (celecoxib 200mg) : once daily, for 12 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. morning : 1 tab. of placebo Entelon 150mg + 1 cap. of active Celebrex~2. evening : 1 tab. of placebo Entelon 150mg
Study: NCT01768520
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. morning : 1 tab. of placebo Entelon 150mg + 1 cap. of placebo Celebrex~2. evening : 1 tab. of placebo Entelon 150mg
Study: NCT01190982
Drug: LEP-ETU
Normalized name: rabies virus vaccine flury-lep strain Injection [RabAvert]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 275 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, 6 Cycles or until progression or unacceptable toxicity develops.
Study: NCT00419068
Drug: Migliol Placebo Oil
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01253915
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 sec/nostril up to 4 times to treat a migraine
Study: NCT00722852
Drug: ketoprofen in Diractin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg (b.i.d.)
Study: NCT00722852
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg (b.i.d.)
Study: NCT00343252
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once weekly, oral, 18 months
Study: NCT00343252
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily, subcutaneous, 18 months
Study: NCT02076178
Drug: Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline cellulose, Opadry film-coating, white OY-S-28876
Study: NCT02076178
Drug: Placebo Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile saline 0.9% Sodium Chloride Injection
Study: NCT00731120
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine placebo-matching capsules